Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Viatris Inc. before investing.

In this article, we go over a few key elements for understanding Viatris Inc.’s stock price such as:

• Viatris Inc.’s current stock price and volume
• Why Viatris Inc.’s stock price changed recently
• Upgrades and downgrades for VTRS from analysts
• VTRS’s stock price momentum as measured by its relative strength

About Viatris Inc. (VTRS)

Before we jump into Viatris Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Want to learn more about Viatris Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Viatris Inc..

Viatris Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Viatris Inc.’s stock price was $17.560.

Viatris Inc. is down 1.13% from its previous closing price of $17.760.

During the last market session, Viatris Inc.’s stock traded between $17.375 and $17.690. Currently, there are approximately 1,155.40 million shares outstanding for Viatris Inc..

Viatris Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Viatris Inc. Stock Price History

Viatris Inc.’s (VTRS) price is currently up 10.58% so far this month.

During the month of July, Viatris Inc.’s stock price has reached a high of $18.070 and a low of $15.920.

Over the last year, Viatris Inc. has hit prices as high as $18.070 and as low as $8.625. Year to date, Viatris Inc.’s stock is up 41.04%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Viatris Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded Viatris Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Viatris Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Viatris Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Viatris Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Viatris Inc. (VTRS) by visiting AAII Stock Evaluator.

Relative Price Strength of Viatris Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Viatris Inc. has a weighted four-quarter relative price strength of 14.47%, which translates to a Momentum Score of 88 and is considered to be Very Strong.

Want to learn more about how Viatris Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Viatris Inc. Stock Price: Bottom Line

As of July 31, 2026, Viatris Inc.’s stock price is $17.560, which is down 1.13% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Viatris Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.